Plain-English translation of NCT06503848 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is trying to understand why some people with migraines respond well to while others don't. Researchers want to identify the differences between patients whose migraines improve with this medication and those whose don't. By understanding these differences, doctors hope to offer more personalized migraine treatment in the future.
Many people with migraines don't get good relief from the medications currently available, and doctors don't yet understand why some patients respond better than others to the same treatment. This study aims to close that gap so treatment can be tailored to each person's needs.
You likely qualify if…
You likely don't qualify if…
When you have a migraine, you'll take 50 milligrams as directed and then record details about your headache symptoms and whether the medication helped. You'll do this for four separate migraine attacks over the course of the study. All of your responses will be entered online or by mail, so you can participate from home.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Spain
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Collaborators
Instituto de Salud Carlos III
Enrollment target
~108 participants
Started
January 2024
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 45 Years
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marta Torres-Ferrús, PhD
Hospital Universitari Vall d'Hebron, Headache & Neurological Pain Research Group
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.